AMGN

SEC source: 0001127602-13-008113 · form4.xml · derivative · entry 8

HERRINGER FRANK C · CIK 0001171694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2013-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-008113 · form4.xml · nonDerivative · entry 4

HERRINGER FRANK C · CIK 0001171694 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Frank C & Maryellen C Herringer 1995 Family Trust

Disclosed balance after: 3,639

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

SEC source: 0001127602-13-008113 · form4.xml · nonDerivative · entry 3

HERRINGER FRANK C · CIK 0001171694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,262

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

F2 · balance_after: These shares include 334 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-008113 · form4.xml · nonDerivative · entry 2

HERRINGER FRANK C · CIK 0001171694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,080

SEC source: 0001127602-13-008113 · form4.xml · nonDerivative · entry 1

HERRINGER FRANK C · CIK 0001171694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-005447 · form4.xml · derivative · entry 3

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2014-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-005447 · form4.xml · nonDerivative · entry 2

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,304

F1 · price: The price reported is an average price. The prices ranged from $86.93 to $86.97 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

SEC source: 0001127602-13-005447 · form4.xml · nonDerivative · entry 1

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,304

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-003074 · form4.xml · derivative · entry 1

ECKERT ROBERT · CIK 0001194256 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2023-01-28

SEC source: 0001127602-13-003252 · form4.xml · nonDerivative · entry 1

SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,984

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,425 RSUs which fully vest on 4/28/2013; 2,900 RSUs which vest in two equal annual installments of 1,450 each commencing 4/26/2013; 22,081 RSUs which fully vest on 12/31/2014; 11,200 RSUs which vest in two equal installments of 3,696 each on 4/25/2013 and 4/25/2014 and one installment of 3,808 on 4/25/2015; 6,141 RSUs which vest in three installments of 2,026, 2,027 and 2,088 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 5,374 RSUs which vest in two equal installments of 1,773 each on 1/28/2015 and 1/28/2016 and one installment of 1,828 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 83 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-003255 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,737

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 129 RSUs which fully vest on 4/28/2013; 263 RSUs which vest in two installments of 131 and 132 on 4/26/2013 and 4/26/2014, respectively; 2,000 RSUs which vest in two equal annual installments of 1,000 each commencing 10/28/2013; 1,493 RSUs which vest in three installments of 492, 493 and 508 on 4/25/2013, 4/25/2014 and 4/25/2015, respectively; 1,200 RSUs which vest in two equal installments of 396 each on 4/27/2014 and 4/27/2015 and one installment of 408 on 4/27/2016; 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively; and 2,103 RSUs which vest in three installments of 693, 694 and 716 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 38 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-003257 · form4.xml · nonDerivative · entry 1

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,980

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 850 RSUs which fully vest on 4/28/2013; 1,750 RSUs which vest in two equal annual installments of 875 each commencing 4/26/2013; 4,500 RSUs which vest in two equal installments of 1,485 each on 4/25/2013 and 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 257 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-003259 · form4.xml · nonDerivative · entry 1

HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,821

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 17,753 RSUs which vest in one installment of 8,744 on 3/2/2013 and one installment of 9,009 on 3/2/2014; 22,619 RSUs which vest in two equal installments of 7,690 each on 3/2/2013 and 3/2/2014 and one installment of 7,239 on 3/2/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-003262 · form4.xml · nonDerivative · entry 1

Peacock Jonathan M · CIK 0001500241 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,950

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 50,000 RSUs which vest in two equal annual installments of 25,000 each commencing 10/28/2013; 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-003266 · form4.xml · nonDerivative · entry 1

Harper Sean E · CIK 0001541946 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,981

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-003271 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,171

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/28/2013; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/26/2013; 3,000 RSUs which vest in two equal annual installments of 1,500 each commencing 4/26/2013; 21,000 RSUs which vest in two equal installments of 6,930 each on 4/25/2013 and 4/25/2014 and one installment of 7,140 on 4/25/2015; 20,938 RSUs which vest in three installments of 6,909, 6,910 and 7,119 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 18,693 RSUs which vest in three installments of 6,168, 6,169 and 6,356 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 285 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-003273 · form4.xml · nonDerivative · entry 1

MCNAMEE BRIAN M · CIK 0001183885 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,265

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,425 RSUs which fully vest on 4/28/2013; 2,900 RSUs which vest in two equal annual installments of 1,450 each commencing 4/26/2013; 22,081 RSUs which fully vest on 12/31/2014; 7,500 RSUs which vest in two equal installments of 2,475 each on 4/25/2013 and 4/25/2014 and one installment of 2,550 on 4/25/2015; 4,466 RSUs which vest in three installments of 1,473, 1,474 and 1,519 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 4,439 RSUs which vest in three installments of 1,464, 1,465 and 1,510 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-12-034798 · form4.xml · derivative · entry 3

Bradway Robert A · CIK 0001396482 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2013-07-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-034798 · form4.xml · nonDerivative · entry 2

Bradway Robert A · CIK 0001396482 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,478

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/28/2013; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/26/2013; 3,000 RSUs which vest in two equal annual installments of 1,500 each commencing 4/26/2013; 21,000 RSUs which vest in two equal installments of 6,930 each on 4/25/2013 and 4/25/2014 and one installment of 7,140 on 4/25/2015; and 20,938 RSUs which vest in three installments of 6,909, 6,910 and 7,119 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 285 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-12-034798 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-033766 · form4.xml · derivative · entry 4

BALTIMORE DAVID · CIK 0001185858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires 2013-01-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-033766 · form4.xml · nonDerivative · entry 3

BALTIMORE DAVID · CIK 0001185858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,526

F1 · price: The price reported is an average price. The prices ranged from $88.99 to $89.025 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

SEC source: 0001127602-12-033766 · form4.xml · nonDerivative · entry 2

BALTIMORE DAVID · CIK 0001185858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,326

SEC source: 0001127602-12-033766 · form4.xml · nonDerivative · entry 1

BALTIMORE DAVID · CIK 0001185858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,526

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-033403 · form4.xml · derivative · entry 7

SCHAEFFER LEONARD D · CIK 0001016369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2016-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-033403 · form4.xml · derivative · entry 6

SCHAEFFER LEONARD D · CIK 0001016369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2015-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-033403 · form4.xml · derivative · entry 5

SCHAEFFER LEONARD D · CIK 0001016369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2014-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-033403 · form4.xml · nonDerivative · entry 4

SCHAEFFER LEONARD D · CIK 0001016369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,329

F1 · price: The price reported is an average price. The prices ranged from $87.90 to $87.97 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 74 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-12-033403 · form4.xml · nonDerivative · entry 3

SCHAEFFER LEONARD D · CIK 0001016369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-033403 · form4.xml · nonDerivative · entry 2

SCHAEFFER LEONARD D · CIK 0001016369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-033403 · form4.xml · nonDerivative · entry 1

SCHAEFFER LEONARD D · CIK 0001016369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032313 · form4.xml · derivative · entry 3

BIONDI FRANK · CIK 0001032669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2013-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032313 · form4.xml · nonDerivative · entry 2

BIONDI FRANK · CIK 0001032669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,833

F1 · price: The price reported is an average price. The prices ranged from $88.10 to $88.12 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 250 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-12-032313 · form4.xml · nonDerivative · entry 1

BIONDI FRANK · CIK 0001032669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,833

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032078 · form4.xml · derivative · entry 7

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2014-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032078 · form4.xml · derivative · entry 6

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2013-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032078 · form4.xml · derivative · entry 5

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires 2013-01-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032078 · form4.xml · nonDerivative · entry 4

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,783

F1 · price: The price reported is an average price. The prices ranged from $87.095 to $87.13 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 108 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-12-032078 · form4.xml · nonDerivative · entry 3

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,783

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032078 · form4.xml · nonDerivative · entry 2

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,783

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-032078 · form4.xml · nonDerivative · entry 1

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,783

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-029207 · form4.xml · nonDerivative · entry 2

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,607

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 129 RSUs which fully vest on 4/28/2013; 263 RSUs which vest in two installments of 131 and 132 on 4/26/2013 and 4/26/2014, respectively; 2,000 RSUs which vest in two equal annual installments of 1,000 each commencing 10/28/2013; 1,493 RSUs which vest in three installments of 492, 493 and 508 on 4/25/2013, 4/25/2014 and 4/25/2015, respectively; 1,200 RSUs which vest in two equal installments of 396 each on 4/27/2014 and 4/27/2015 and one installment of 408 on 4/27/2016; and 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 11 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-12-029209 · form4.xml · nonDerivative · entry 1

Peacock Jonathan M · CIK 0001500241 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,438

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 50,000 RSUs which vest in two equal annual installments of 25,000 each commencing 10/28/2013; 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 82 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-12-029161 · form4.xml · nonDerivative · entry 2

SHARER KEVIN W · CIK 0001185618 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Living Trust

Disclosed balance after: 0

SEC source: 0001127602-12-029161 · form4.xml · nonDerivative · entry 1

SHARER KEVIN W · CIK 0001185618 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Living Trust

Disclosed balance after: 4,074

SEC source: 0001127602-12-029207 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,974

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 10/26/2014, 10/26/2015 and 10/26/2016, respectively.

SEC source: 0001127602-12-029163 · form4.xml · nonDerivative · entry 1

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,783

F1 · balance_after: These shares include 108 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-12-029087 · form4.xml · derivative · entry 9

SHARER KEVIN W · CIK 0001185618 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 193,609 shares

Expires 2013-04-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-029087 · form4.xml · derivative · entry 8

SHARER KEVIN W · CIK 0001185618 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,391 shares

Expires 2013-04-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-12-029087 · form4.xml · nonDerivative · entry 6

SHARER KEVIN W · CIK 0001185618 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Living Trust

Disclosed balance after: 5,494

F5 · price: The price reported is an average price. The prices ranged from $88.62 to $89.11 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.